ArticleFrontiers in endocrinology2026
Extreme phenotype-derived machine learning reveals susceptibility and resilience signatures for severe diabetic retinopathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mechanisms underlying why some individuals with diabetes develop severe diabetic retinopathy (DR), whereas others remain free of retinal complications despite long-standing disease, remain incompletely understood. We aimed to identify systemic susceptibility and resilience signatures associated with severe DR using an extreme phenotype-derived machine learning framework. Methods: An extreme phenotype cohort was established comprising 712 individuals with diabetes mellitus, including 437 patients with proliferative diabetic retinopathy (PDR; susceptible phenotype) and 275 patients with diabetes duration ≥10 years without retinopathy (resilient phenotype). Clinical and biochemical variables were integrated to develop interpretable machine learning models. The optimal model was further interpreted using SHapley Additive exPlanations (SHAP). An independent community-based diabetic cohort (n=673) was used to evaluate the distribution of susceptibility signatures in real-world populations. Results: LASSO regression identified 21 phenotype-associated features for model development. Among the evaluated algorithms, LightGBM demonstrated the strongest ability to discriminate susceptible and resilient phenotypes, achieving an area under the receiver operating characteristic curve (AUC) of 0.90 (95% CI, 0.84-0.95) in the internal validation cohort. SHAP analysis identified urinary albumin excretion rate (UAER), diabetes duration, serum creatinine, total protein, age, and hypertension duration as the dominant phenotype-defining features. Notably, UAER exhibited a pronounced nonlinear association with susceptibility scores, suggesting a close link between renal microvascular injury and vulnerability to severe DR. When applied to the community cohort, the susceptibility signature showed limited discrimination in the overall population (AUC = 0.54) but became progressively enriched among individuals with greater metabolic burden, reaching an AUC of 0.71 in participants with fasting blood glucose ≥9.0 mmol/L. Conclusion: Using an extreme phenotype-derived machine learning framework, we identified systemic susceptibility and resilience signatures associated with severe diabetic retinopathy. Renal dysfunction, albuminuria, glycemic burden, and disease duration emerged as key phenotype-defining characteristics. These signatures became increasingly enriched in metabolically stressed individuals, supporting the concept that severe diabetic retinopathy arises through the interaction between intrinsic biological susceptibility and cumulative metabolic exposure. This framework may provide new insights into disease heterogeneity and facilitate future precision risk stratification strategies in diabetic eye disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.